Donepezil as a new therapeutic potential in KCNQ2- and KCNQ3-related autism.

Nissenkorn A, Bar L, Ben-Bassat A, Rothstein L, Abdelrahim H, Sokol R, Gabis LV, Attali B

Open source

DOI
10.3389/fncel.2024.1380442
Published
2024
Container
Frontiers in cellular neuroscience
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fncel.2024.1380442,
  title = {Donepezil as a new therapeutic potential in KCNQ2- and KCNQ3-related autism.},
  author = {Nissenkorn A and Bar L and Ben-Bassat A and Rothstein L and Abdelrahim H and Sokol R and Gabis LV and Attali B},
  year = {2024},
  journal = {Frontiers in cellular neuroscience},
  doi = {10.3389/fncel.2024.1380442},
  url = {https://doi.org/10.3389/fncel.2024.1380442}
}

RIS

TY  - JOUR
TI  - Donepezil as a new therapeutic potential in KCNQ2- and KCNQ3-related autism.
AU  - Nissenkorn A
AU  - Bar L
AU  - Ben-Bassat A
AU  - Rothstein L
AU  - Abdelrahim H
AU  - Sokol R
AU  - Gabis LV
AU  - Attali B
PY  - 2024
JO  - Frontiers in cellular neuroscience
DO  - 10.3389/fncel.2024.1380442
UR  - https://doi.org/10.3389/fncel.2024.1380442
ER  - 

APA

A, N., L, B., A, B., L, R., H, A., R, S., LV, G., & B, A. (2024). Donepezil as a new therapeutic potential in KCNQ2- and KCNQ3-related autism.. Frontiers in cellular neuroscience. https://doi.org/10.3389/fncel.2024.1380442

Source records